Anavex Life Sciences Corp (AVXL)

[falconer66a]

Seminal Findings in the Anavex 3-71 Rat Study

I’ve copied what I believe are the four most important headline findings in the referenced paper, where Anavex 3-71 was administered to neurologically-diseased rats (merely in their drinking water; no injections, not intravenous).

https://anavex.com/wp-content/uploads/170330_ADPD-Vienna_HH-update.pdf

Make of these statements in the paper what you will:

1. AF710B [Anavex 3-71] fully reverts the cognitive deficit in aged McGill tg rats

Is there any existing drug that safely, persistently restores full cognition?

2. AF710B [Anavex 3-71] reduces AD-Iike amyloid pathology in McGill tg rats

Amyloid pathology is the main, pathologic feature of Alzheimer’s disease.

3. AF710B [Anavex 3-71] reduces inflammation in McGill tg rats

Inflammation is a root cause or severe complication of a majority of human diseases.

4. AF710B [Anavex 3-71] has synaptogenic properties

Ability to create or restore functioning nerve junctions (“synaptogenesis”) fixes a host of central nervous system diseases and dysfunctions.

“Yea, but thems was rats. We’s people. Don’t mean nothin!”

Ok, then. Let’s see what happens with Anavex 3-71 in real humans.

Anavex Life Sciences Corp has indicated they want to go that route, with people suffering from frontotemporal dementia (FTD). With the exception of amyloid pathology, FTD has all of the above (instead, it has tau pathology; which Anavex 3-71 may also remediate or prevent).